• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对急性髓细胞白血病患者的靶向基因测序结果是否已准备好用于临床决策?

Are results of targeted gene sequencing ready to be used for clinical decision making for patients with acute myelogenous leukemia?

机构信息

Division of Hematologic Malignancies and Cell Therapy, Duke University Medical Center, 2400 Pratt Street, Suite 9010, Durham, NC 27710, USA.

出版信息

Curr Hematol Malig Rep. 2013 Jun;8(2):149-55. doi: 10.1007/s11899-013-0161-6.

DOI:10.1007/s11899-013-0161-6
PMID:23595294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3690575/
Abstract

Acute myeloid leukemia (AML) is the most common acute leukemia in the USA, which despite recent advances, continues to have a high mortality rate. It is a biologically active disease characterized by numerous cytogenetic abnormalities and multiple genetic mutations. Next-generation sequencing (NGS) will perhaps not reveal all the factors that make AML a complex disease, but does have the potential to affect the diagnosis and risk stratification of AML patients and allow more personalized therapy. AML cells are easy to obtain from the patient and samples are only minimally contaminated with normal cells, which makes it an attractive cancer to study. Several studies have now demonstrated that the majority of AML patients are cytogenetically normal and the genome of these patients may contain fewer mutations than cancer genomes that are highly aneuploidy, suggesting that mutations in diploid genomes are more likely to be pathogenetically relevant. Whole-genome, exome, transcriptome, and targeted gene sequencing studies have been conducted successfully in AML and have provided with valuable information. The challenges for the future include: reducing the cost of sequencing, understanding epigenetic changes, managing data across various platforms, separating the driver mutations from the sea of passenger mutations, and finally, educating future generations to allow a better understanding and easy availability of these complex methodologies.

摘要

急性髓系白血病(AML)是美国最常见的急性白血病,尽管最近取得了进展,但死亡率仍然很高。它是一种具有生物活性的疾病,其特征是存在许多细胞遗传学异常和多种基因突变。下一代测序(NGS)可能无法揭示使 AML 成为复杂疾病的所有因素,但确实有可能影响 AML 患者的诊断和风险分层,并允许进行更个性化的治疗。AML 细胞很容易从患者中获得,并且样本仅轻微污染正常细胞,这使其成为一种有吸引力的癌症研究对象。现在有几项研究表明,大多数 AML 患者的细胞遗传学正常,这些患者的基因组可能比高度非整倍体的癌症基因组包含更少的突变,这表明二倍体基因组中的突变更可能与发病机制相关。全基因组、外显子组、转录组和靶向基因测序研究已在 AML 中成功进行,并提供了有价值的信息。未来的挑战包括:降低测序成本、了解表观遗传变化、跨多个平台管理数据、将驱动突变与乘客突变区分开,以及最终教育后代,使他们能够更好地理解和方便地使用这些复杂的方法。

相似文献

1
Are results of targeted gene sequencing ready to be used for clinical decision making for patients with acute myelogenous leukemia?针对急性髓细胞白血病患者的靶向基因测序结果是否已准备好用于临床决策?
Curr Hematol Malig Rep. 2013 Jun;8(2):149-55. doi: 10.1007/s11899-013-0161-6.
2
The use of molecular genetics to refine prognosis in acute myeloid leukemia.
Curr Hematol Malig Rep. 2014 Jun;9(2):148-57. doi: 10.1007/s11899-014-0208-3.
3
Identification of somatic mutations using whole-exome sequencing in Korean patients with acute myeloid leukemia.在韩国急性髓系白血病患者中使用全外显子组测序鉴定体细胞突变。
BMC Med Genet. 2017 Mar 1;18(1):23. doi: 10.1186/s12881-017-0382-y.
4
Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.基于二代测序的中危急性髓系白血病患者的突变谱及风险分层
Oncotarget. 2016 May 31;7(22):32065-78. doi: 10.18632/oncotarget.7028.
5
Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia.全外显子组测序揭示了儿童急性髓系白血病中的基因突变谱和克隆进化模式。
Br J Haematol. 2016 Nov;175(3):476-489. doi: 10.1111/bjh.14247. Epub 2016 Jul 29.
6
Pathology Consultation on Gene Mutations in Acute Myeloid Leukemia.急性髓系白血病基因突变的病理会诊
Am J Clin Pathol. 2015 Oct;144(4):539-54. doi: 10.1309/AJCP77ZFPUQGYGWY.
7
Recurring mutations found by sequencing an acute myeloid leukemia genome.通过对急性髓系白血病基因组进行测序发现的复发性突变。
N Engl J Med. 2009 Sep 10;361(11):1058-66. doi: 10.1056/NEJMoa0903840. Epub 2009 Aug 5.
8
Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.使用基于测序的分子谱分析对急性髓系白血病风险分层模型进行验证。
Leukemia. 2017 Oct;31(10):2029-2036. doi: 10.1038/leu.2017.48. Epub 2017 Feb 7.
9
Genomics of AML: clinical applications of next-generation sequencing.AML 的基因组学:下一代测序的临床应用。
Hematology Am Soc Hematol Educ Program. 2011;2011:30-5. doi: 10.1182/asheducation-2011.1.30.
10
Molecular genetics of AML.急性髓系白血病的分子遗传学。
Best Pract Res Clin Haematol. 2012 Dec;25(4):409-14. doi: 10.1016/j.beha.2012.10.002. Epub 2012 Oct 23.

引用本文的文献

1
Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations.急性髓系白血病中19个候选基因的突变分析表明DNMT3A突变具有重要意义。
Oncotarget. 2016 Aug 23;7(34):54825-54837. doi: 10.18632/oncotarget.10240.
2
Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory Analysis.急性白血病中的III类受体酪氨酸激酶——生物学功能与现代实验室分析
Biomark Insights. 2015 Aug 5;10(Suppl 3):1-14. doi: 10.4137/BMI.S22433. eCollection 2015.
3
BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers.BreaKmer:利用k-mer在靶向大规模平行测序数据中检测结构变异
Nucleic Acids Res. 2015 Feb 18;43(3):e19. doi: 10.1093/nar/gku1211. Epub 2014 Nov 26.
4
Genomic tools in acute myeloid leukemia: From the bench to the bedside.基因组学工具在急性髓细胞白血病中的应用:从实验室到临床。
Cancer. 2014 Apr 15;120(8):1134-44. doi: 10.1002/cncr.28552. Epub 2014 Jan 28.
5
National Institutes of Health Center for Regenerative Medicine: putting science into practice.美国国立卫生研究院再生医学中心:将科学付诸实践。
Stem Cells Dev. 2013 Dec;22 Suppl 1(Suppl 1):4-7. doi: 10.1089/scd.2013.0437.
6
Clinical advances in molecular biomarkers for cancer diagnosis and therapy.癌症诊断和治疗中分子生物标志物的临床进展。
Int J Mol Sci. 2013 Jul 16;14(7):14771-84. doi: 10.3390/ijms140714771.

本文引用的文献

1
Opportunities and methods for studying alternative splicing in cancer with RNA-Seq.利用 RNA-Seq 研究癌症中可变剪接的机会和方法。
Cancer Lett. 2013 Nov 1;340(2):179-91. doi: 10.1016/j.canlet.2012.11.010. Epub 2012 Nov 27.
2
Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data.靶向、短读长、下一代测序数据中 FLT3 内部串联重复的检测。
J Mol Diagn. 2013 Jan;15(1):81-93. doi: 10.1016/j.jmoldx.2012.08.001. Epub 2012 Nov 14.
3
Genomics of acute myeloid leukemia: the next generation.急性髓细胞白血病的基因组学:下一代。
Front Oncol. 2012 May 1;2:40. doi: 10.3389/fonc.2012.00040. eCollection 2012.
4
Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia.白血病临床相关基因突变和易位的靶向二代测序。
Mod Pathol. 2012 Jun;25(6):795-804. doi: 10.1038/modpathol.2012.29. Epub 2012 Mar 16.
5
Genomics of AML: clinical applications of next-generation sequencing.AML 的基因组学:下一代测序的临床应用。
Hematology Am Soc Hematol Educ Program. 2011;2011:30-5. doi: 10.1182/asheducation-2011.1.30.
6
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.全外显子组测序鉴定出正常核型急性髓细胞白血病中的 BCOR 体细胞突变。
Blood. 2011 Dec 1;118(23):6153-63. doi: 10.1182/blood-2011-07-365320. Epub 2011 Oct 19.
7
Somatic mutations in acute promyelocytic leukemia (APL) identified by exome sequencing.通过外显子组测序鉴定的急性早幼粒细胞白血病(APL)中的体细胞突变。
Leukemia. 2011 Sep;25(9):1519-22. doi: 10.1038/leu.2011.114. Epub 2011 May 24.
8
Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.应用全基因组测序诊断隐匿性融合癌基因
JAMA. 2011 Apr 20;305(15):1577-84. doi: 10.1001/jama.2011.497.
9
Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.通过对一位治疗相关性 AML 患者进行全基因组测序,鉴定出一种新的 TP53 癌症易感性突变。
JAMA. 2011 Apr 20;305(15):1568-76. doi: 10.1001/jama.2011.473.
10
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia.外显子组测序鉴定出急性单核细胞白血病中 DNA 甲基转移酶基因 DNMT3A 的体细胞突变。
Nat Genet. 2011 Mar 13;43(4):309-15. doi: 10.1038/ng.788.